Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
Ironwood Pharmaceuticals, Inc. will host its Q3 2023 investor update conference call on November 9, 2023. The call will be available for replay via telephone and the webcast will be archived on Ironwood's website for 14 days.
Positive
Ironwood Pharmaceuticals will provide updates on its Q3 2023 performance, which could positively impact stock price.
Negative
No negative takes available.
10/26/2023 - 04:01 PM
BOSTON --(BUSINESS WIRE)--
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 9, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada ) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
The call will be available for replay via telephone starting Thursday, November 9, 2023 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 23, 2023. To listen to the replay, dial (800) 770-2030 (U.S. and Canada ) or (647) 362-9199 (international) using conference ID number 4671230. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading global gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years-old. Ironwood is also advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF), as well as several earlier stage assets. Building upon our history of GI innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.
Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts , and has operations in Basel, Switzerland .
We routinely post information that may be important to investors on our website at www.ironwoodpharma.com . In addition, follow us on Twitter and on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20231026193200/en/
Investors:
Greg Martini, 617-374-5230
gmartini@ironwoodpharma.com
Matt Roache, 617-621-8395
mroache@ironwoodpharma.com
Media:
Beth Calitri, 978-417-2031
bcalitri@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.
When will Ironwood Pharmaceuticals host its Q3 2023 investor update conference call?
Ironwood Pharmaceuticals will host its Q3 2023 investor update conference call on November 9, 2023.
Where can I access the webcast of the conference call?
You can access the webcast of the conference call on Ironwood's website in the Investors section.
How long will the replay of the conference call be available?
The replay of the conference call will be available via telephone for two weeks, starting from November 9, 2023.
For how long will the archived webcast be available?
The archived webcast will be available on Ironwood's website for 14 days, starting approximately one hour after the call has completed.
Ironwood Pharmaceuticals Inc
IRWD Rankings
#3314 Ranked by Stock Gains
IRWD Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Boston
About IRWD
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b